Introduction {#s1}
============

Pulmonary thromboembolism (PTE) is a major cause of cardiovascular mortality worldwide with a case fatality rate of 15% within the early post-diagnosis phase.^[@R1]^ It incurs 7-10 billion dollars annually to the healthcare system only in the United States.^[@R2]^ Risk stratification and prognostication is of great importance in patients who present to emergency department with acute PTE, and follows two main purposes: Identifying low-risk patients that can be treated as an outpatient and finding high-risk cases that may benefit from second-line therapies such as thrombolysis or surgical embolectomy. Beside risk stratification tools such as Pulmonary Embolism Severity Index (PESI),^[@R3],[@R4]^ readily available blood parameters have been recently proposed to be predictors of clinical outcome in venous thromboembolism.

Given the established role of platelets in thrombogenesis, platelet activation is considered as an expected phenomenon in PTE. Mean platelet volume (MPV) and platelet distribution width (PDW) are markers of platelet production and activation. Higher MPV (i.e. larger platelets) is shown to be associated with the presence of more granules, higher levels of thromboxane A2, rapid aggregation with collagen, and more glycoprotein Ib and IIb/IIIa receptors.^[@R5],[@R6]^

Furthermore, the Leukocytes' physiologic response to stress usually presents with an increase in the sympathetic activity and cortisol levels as well as an increase in the number of neutrophils which is associated with a decrease in the number of lymphocytes. This leads to the extravasation of neutrophils into the affected area.^[@R7]^ Platelet-lymphocyte ratio (PLR), as a surrogate marker of inflammation, may be used to explore the link between thrombosis and inflammation in PTE, which is mediated by the production of reactive oxygen species and higher levels of myeloperoxidase enzyme,^[@R8]^ the consequent oxidative stress,^[@R9]^ and the release of pro-inflammatory cytokines such as IL-6 and TNF-α.^[@R10],[@R11]^

In this study, we measured the levels of MPV, PLR and PDW in a cohort of patients who were diagnosed with acute PTE in emergency department to investigate the predictive performance of these biomarkers in predicting adverse outcomes in this patient population.

Materials and Methods {#s2}
=====================

In a single-center prospective cohort study, 492 patients with a confirmed diagnosis of acute pulmonary embolism were enrolled at Madani Heart Hospital in Tabriz, Iran, between March 2011 and March 2015.

Study population {#s2-1}
----------------

Patients with an age older than 18 years presenting to hospital with chest pain or dyspnea with a primary diagnosis of acute PTE were included. The diagnosis of acute PTE has been made using multidetector computed tomography (CT) angiography. CT angiography result was considered diagnostic for PTE in the presence of intraluminal filling defect or arterial cut-off. In patients who were contraindicated to undergo CT angiography because of a history of contrast allergy, patients with severe renal dysfunction (estimated glomerular filtration rates \<30 mL/min) or pregnant women, the diagnosis of acute PTE was established using ventilation/perfusion (V/Q) scintigraphy and high probability scans were considered as diagnostic. Patients were excluded if they were admitted \>24 hours after the symptom onset, if they had a prior history of PTE or an underlying disease limiting the life expectancy to less than one month (e.g. major trauma or high-grade cancer).

Demographic information, comorbidities, admission vital signs, echocardiographic findings, admission laboratory data before receiving treatment as well as main treatment protocol and survival status during hospitalization of included patients were recorded in prepared questionnaires by a trained physician.

We calculated simplified PESI score using variables of age \>80 years, pulse rate ≥110 beats/minute, systolic blood pressure \<100 mm Hg, history of cancer, chronic cardiopulmonary disease, and arterial oxygen saturation \<90%.^[@R3]^

Laboratory measurements {#s2-2}
-----------------------

Venous blood samples on admission were obtained and collected in citrated tubes containing EDTA potassium salt additive as an anticoagulant. Blood samples were transferred to and analyzed by hospital laboratory within one hour. Total white blood cell, neutrophil, lymphocyte and platelet counts, hemoglobin, PDW and MPV were recorded for each patient. Biochemical analysis was performed to measure blood urea nitrogen (BUN), creatinine and blood glucose. For performing differential complete blood count analyses, an automated Coulter CBC H1 counter, which was calibrated on a daily basis was used. PLR was calculated as the platelet count divided by the absolute lymphocyte count per one cubic millimeter (mm^3^). NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count per one cubic millimeter (mm^3^).

Follow up {#s2-3}
---------

Patients were followed during the index hospital stay and regularly afterwards in the outpatient clinics for one year.

Outcomes {#s2-4}
--------

The primary endpoint of interest in this study was in-hospital all-cause mortality. Major adverse cardiopulmonary events (MACPE), defined as a composite of the all-cause mortality and the need for thrombolysis, mechanical ventilation and surgical embolectomy during the index hospitalization and all-cause death during follow-up were secondary endpoints.

Statistical analysis {#s2-5}
--------------------

Mean and standard deviation (SD) were presented for continuous variables and frequency (%) for categorical variables. For comparison between groups with and without clinical events, the independent *t* test, Mann-Whitney U rank sum test and the Pearson χ^2^ test, were used.

Receiver operating characteristics (ROC) curve was used to determine the area under the curve (AUC) and to identify the optimal cut-off point of MPV, PDW, PLR and the simplified PESI score in predicting different clinical outcomes including in-hospital death, in-hospital MACPE, and follow-up death. Pearson correlation test was done between MPV and total platelet counts, cardiac troponin levels, and systolic pulmonary arterial pressure as well as between platelet indices and the PESI risk score. All data analyses were performed using SPSS (Version 21.0; IBM SPSS Corporation, Chicago, IL) and *P* values \<0.05 were considered statistically significant.

Results {#s3}
=======

In this prospective cohort study, 492 patients with confirmed acute PTE were enrolled. The mean age was 62.1 ± 17.1 years and 48% of cases (236 patients) were male. Patient demographics, clinical presentations, and baseline laboratory and imaging findings are summarized in [Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}.

###### Patient characteristics in the study population and in groups with and without major adverse cardiopulmonary events (MACPE)

  --------------------------------- ------------------- ------------------------ --------------------------- -------------------
                                    **Total (n=492)**   **With MACPE (n=151)**   **Without MACPE (n=341)**   ***P*** **value**
  Age, year                         62.1 ± 17.2         58.9 ± 18.1              63.5 ± 16.6                 0.006
  Male sex, n(%)                    236 (48.0)          77 (51.0)                159 (46.6)                  0.371
  Seasonal distribution                                                                                      
  Spring                            122 (24.8)          33 (21.9)                89 (26.2)                   0.397
  Summer                            142 (28.9)          46 (30.5)                96 (28.2)                   
  Fall                              111 (22.6)          40 (26.5)                71 (20.9)                   
  Winter                            116 (23.6)          32 (21.2)                84 (24.7)                   
  Comorbidities                                                                                              
  Hypertension                      206 (42.0)          55 (36.7)                151 (44.3)                  0.115
  Diabetes mellitus                 72 (16.0)           24 (18.8)                48 (14.9)                   0.309
  Congestive heart failure          39 (7.9)            8 (5.3)                  31 (9.1)                    0.151
  Hyperlipidemia on statins         50 (21.6)           15 (21.4)                35 (21.6)                   0.976
  COPD                              43 (8.7)            9 (6.0)                  34 (10.0)                   0.146
  Past/current smoker               63 (14.0)           22 (17.2)                41 (12.7)                   0.215
  Concurrent DVT                    16 (5.2)            5 (5.7)                  11 (5.0)                    0.781
  Active Cancer                     34 (6.9)            10 (6.6)                 24 (7.0)                    0.867
  Recent history of immobility      98 (19.9)           31 (20.5)                67 (19.6)                   0.821
  Recent long distance travelling   8 (1.6)             3 (2.0)                  5 (1.5)                     0.706
  Oral contraceptives               20 (4.1)            4 (2.6)                  16 (4.7)                    0.290
  --------------------------------- ------------------- ------------------------ --------------------------- -------------------

COPD: chronic obstructive pulmonary disease.

###### Clinical presentation and imaging findings in patients with and without major adverse cardiopulmonary events (MACPE)

  ------------------------------ ------------------- ------------------------ --------------------------- -------------
                                 **Total (n=492)**   **With MACPE (n=151)**   **Without MACPE (n=341)**   **P value**
  Hypothermia                    131 (34.9)          38 (34.9)                93 (35.0)                   0.985
  Dyspnea                        401 (81.5)          122 (80.8)               279 (81.8)                  0.787
  Tachypnea \> 20 bpm            245 (57.0)          77 (60.2)                168 (55.6)                  0.386
  Pleuritic chest pain           68 (13.8)           12 (7.9)                 56 (16.4)                   0.012
  Substernal chest pain          81 (16.5)           20 (13.2)                61 (17.9)                   0.200
  Syncope                        55 (11.2)           31 (20.5)                24 (7.0)                    \<0.001
  Tachycardia \> 100 bpm         229 (47.6)          88 (60.3)                141 (42.1)                  \<0.001
  RV enlargement                 310 (64.2)          128 (85.3)               182 (54.7)                  \<0.001
  RV diameter on CT (mm)         4.62 ± 0.94         4.46 ± 0.81              4.66 ± 0.98                 0.471
  RV dysfunction                 288 (59.6)          123 (82.0)               165 (49.5)                  \<0.001
  Right/Left ventricular ratio   0.79 ± 0.19         0.75 ± 0.14              0.81 ± 0.20                 0.300
  Systolic pulmonary pressure    50.6 ± 21.3         55.2 ± 20.0              48.0 ± 21.7                 0.003
  Clot on echocardiogram         33 (6.9)            27 (18.1)                6 (1.8)                     \<0.001
  Presence of saddle embolus     51 (12.5)           32 (25.8)                19 (6.7)                    \<0.001
  Segmental pulmonary emboli     119 (29.7)          19 (15.4)                100 (36.0)                  \<0.001
  ------------------------------ ------------------- ------------------------ --------------------------- -------------

RV: right ventricle.

###### Laboratory findings in patients with and without major adverse cardiopulmonary events (MACPE)

  ------------------------------------------ ------------------- ------------------------ --------------------------- -------------
                                             **Total (n=492)**   **With MACPE (n=151)**   **Without MACPE (n=341)**   **P value**
  Laboratory findings                                                                                                 
  Hemoglobin (g/dL)                          12.8 ± 2.4          12.8 ± 2.5               12.7 ± 2.3                  0.607
  White blood cell count (103 cells/nL)      11.3 ± 9.3          13.9 ± 15.5              10.2 ± 3.9                  0.005
  Neutrophil lymphocyte ratio                6.2 ± 6.2           6.8 ± 6.2                5.8 ± 6.2                   0.206
  Platelets (10^3^ counts/nL)                205.0 ± 84.9        183.6 ± 76.9             214.3 ± 86.6                \<0.001
  Mean platelet volume (femtoliter)          9.9 ± 1.0           10.1 ± 1.0               9.9 ± 1.0                   0.019
  Platelet distribution width                13.5 ± 6.1          13.6 ± 2.7               13.5 ± 7.0                  0.914
  Platelet lymphocyte ratio (PLR)            14.7 ± 14.5         15.7 ± 16.5              14.2 ± 13.5                 0.338
  Cardiac troponin I (ng/L)                  0.45 ± 1.12         0.68 ± 1.40              0.35 ± 0.96                 0.019
  Serum d-dimer (µg/mL)                      2.1 ± 2.0           2.4 ± 2.1                1.9 ± 1.9                   0.178
  Arterial partial pressure of O2 (mm Hg)    62.1 ± 28.2         64.4 ± 34.2              60.9 ± 24.6                 0.337
  Arterial partial pressure of CO2 (mm Hg)   37.7 ± 11.1         38.0 ± 11.7              37.5 ± 10.8                 0.708
  Blood glucose                              138.7 ± 77.5        151.5 ± 93.5             133.6 ± 69.7                0.064
  Serum creatinine (mg/dL)                   1.3 ± 1.0           1.2 ± 0.5                1.3 ± 1.2                   0.714
  Alkaline phosphatase (IU/L)                262.0 ± 168.4       223.8 ± 104.9            277.7 ± 186.8               0.055
  Alanine aminotransferase (IU/L)            66.4 ± 86.3         73.2 ± 76.1              63.4 ± 90.6                 0.562
  Aspartate aminotransferase (IU/L)          55.4 ± 75.7         55.0 ± 54.7              55.5 ± 83.5                 0.974
  Serum Total Cholesterol (mg/dL)            167.5 ± 46.1        161.3 ± 38.6             170.0 ± 48.7                0.095
  Low density lipoprotein (mg/dL)            104.0 ± 37.2        96.9 ± 29.8              107.0 ± 39.6                0.034
  Very low density lipoprotein (mg/dL)       31.6 ± 25.5         28.4 ± 10.4              33.2 ± 30.4                 0.598
  ------------------------------------------ ------------------- ------------------------ --------------------------- -------------

Outcomes {#s3-1}
--------

Median length of stay (LOS) at hospital was 9 days (1^st^ and 3^rd^ quartiles 7, 12), and in-hospital death occurred in 42 (8.5%) patients. Ninety-seven patients (19.7%) received fibrinolytic therapy during the index hospitalization. Thirty-five (7.1%) and 23 (4.7%) patients underwent mechanical ventilation and embolectomy, respectively. In total, 151 patients (30.7%) experienced the composite endpoint of all-cause death, thrombolysis, mechanical ventilation and surgical embolectomy during the index hospitalization.

Patients were followed up for a median period of 13 months (interquartile range: 3-23 months). All-cause mortality occurred in 107 patients (21.7%) during the follow-up period.

Platelet indices {#s3-2}
----------------

Total platelet counts were lower in patients who suffered a major adverse event in hospital compared to others (183.6 ± 76.9 vs 214.3 ± 86.6 10^3^ cells/nL; *P* \< 0.001). MPV was 9.9 ± 1.0 fl in the total cohort, and it was higher in those with MACPE as compared to their counterparts (10.1 ± 1.0 vs 9.9 ± 1.0; *P* =0.019).

PDW was 13.5 ± 6.1% in the total cohort and it was not different between groups with and without MACPE (13.6 ± 2.7% vs 13.5 ± 7.0%; *P* \> 0.05). Similarly, PLR was 14.7 ± 14.5 in this study population and was not different between patients who had in-hospital MACPE compared to others (15.7 ± 16.5 vs 14.2 ± 13.5; *P* \> 0.05).

Pearson correlation test revealed that MPV was inversely correlated with the total platelet count \[*r*(490)= - 0.29; *P* \< 0.001\] ([Figure 1](#F1){ref-type="fig"}). There was no correlation between MPV and cardiac troponin levels \[*r*(401)=0.05; *P* =0.3\]. Also there was no correlation between MPV and systolic pulmonary arterial pressure \[*r*(343)=0.03, *P* = 0.4\] in this study population. Unlike MPV (*r*=0.10, *P* = 0.14) and PDW (*r*=0.05, *P*= 0.51), PLR was correlated with the risk level determined by the simplified PESI score (*r*=0.25, *P*= 0.001).

![](jcvtr-12-56-g001){#F1}

Prognostic performance {#s3-3}
----------------------

[Figure 2](#F2){ref-type="fig"} depicts the ROC curves of the predictive performance of different platelet parameters in predicting in-hospital mortality. The predictive performance of these indices in predicting various patient outcomes such as in-hospital mortality, in-hospital MACPE, and death during follow-up period are summarized in [Table 4](#T4){ref-type="table"}. MPV with a cut-off point of 9.85 fl has a sensitivity and specificity of 81% and 50%, respectively in predicting in-hospital mortality in patients with acute PTE, but it had lower performance in predicting composite endpoints (i.e. MACPE AUC 0.58; 95% CI 0.52-0.63) or long-term mortality (AUC 0.54; 95% CI 0.47-0.61).

![](jcvtr-12-56-g002){#F2}

###### The predictive performance of mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR), in prognosticating different clinical outcomes

  ------------------- ------------------ --------------- ----------------- -----------------
                      **AUC (95% CI)**   **Cut-point**   **Sensitivity**   **Specificity**
  MPV                                                                      
  In-hospital death   0.67 (0.58-0.76)   9.85 fl         81.0%             49.6 %
  MACPE               0.58 (0.52-0.63)   9.85 fl         65.6%             52.5%
  Follow up death     0.54 (0.47-0.61)   10.0 fl         51.4%             57.1%
  PDW                                                                      
  In-hospital death   0.66 (0.52-0.80)   13.60           66.7%             65.2%
  MACPE               0.57 (0.51-0.64)   12.35           73.1%             46.7%
  Follow up death     0.50 (0.42-0.59)   13.65           45.0%             66.4%
  PLR                                                                      
  In-hospital death   0.61 (0.50-0.72)   12.8            61.0%             63.2%
  MACPE               0.47 (0.42-0.54)   9.8             52.1%             46.0%
  Follow up death     0.65 (0.58-0.72)   11.4            63.1%             63.5%
  Simplified PESI                                                          
  In-hospital death   0.80 (0.71-0.88)   1.5             77.3%             70.4%
  MACPE               0.69 (0.62-0.77)   0.5             90.5%             42.1%
  Follow up death     0.76 (0.66-0.86)   1.5             60.4%             80.5%
  ------------------- ------------------ --------------- ----------------- -----------------

PDW with the cut-point of 13.6% and PLR with the cut-point of 12.8, respectively had an AUC of 0.66 (95% CI 0.52, 0.80) and 0.61 (95% CI 0.50, 0.72) in predicting in-hospital mortality. In general, platelet indices in our study showed poorer performance when compared to the well-established risk score of the simplified PESI ([Table 4](#T4){ref-type="table"}). In [Table 5](#T5){ref-type="table"}, clinical outcomes were compared between patients with different levels of MPV, PDW and PLR.

###### Clinical outcomes in groups with different levels of mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR)

  ------------------------ ------------------ ------------------- --------- --------------- ---------------- --------- --------------- ---------------- ---------
                           **MPV≤9.85 fl**\   **MPV\>9.85 fl**\   ***P***   **PDW≤13.6**\   **PDW\>13.6**\   ***P***   **PLR≤12.8**\   **PLR\>12.8**\   ***P***
                           **(n=231)**        **(n=261)**                   **(n=241)**     **(n=139)**                **(n=286)**     **(n=182)**      

  SBP \<90 mm Hg           13 (5.7)           26 (10.2)           0.18      18 (7.6)        11 (8.3)         0.76      16 (5.8)        20 (11.1)        \<0.01

  Cardiac arrest           2 (0.9)            2 (0.8)             1.00      2 (0.8)         2 (1.4)          0.62      2 (0.7)         2 (1.1)          0.64

  Vasopressor treatment    3 (2.1)            18 (11.2)           \<0.01    8 (5.3)         10 (11.8)        0.07      15 (8.1)        (5.9)            0.49

  Oxygen saturation (%)    84.9 ±12.8         86.3 ±11.8          0.33      86.0 ±13.2      85.9 ±12.3       0.94      86.0 ±12.5      85.4 ±12.3       0.66

  Blood urea nitrogen      21.5 ±11.9         26.3 ±17.8          0.04      22.1 ±13.3      26.3 ±18.6       0.16      23.3 ±14.4      25.1 ±17.3       0.47

  Fibrinolytic therapy     38 (16.5)          59 (22.6)           0.08      45 (18.7)       21 (15.1)        0.37      58 (20.3)       34 (18.7)        0.67

  Mechanical ventilation   5 (2.2)            30 (11.5)           \<0.01    12 (5.0)        15 (10.8)        0.03      20 (7.0)        15 (8.2)         0.61

  Surgical embolectomy     7 (3.0)            16 (6.1)            0.10      9 (3.7)         9 (6.5)          0.22      14 (4.9)        7 (3.8)          0.59

  Hospital LOS (days)      9.5 ±4.9           11.0 ±9.2           0.02      10.3 ± 6.4      11.5 ±10.6       0.24      10.8 ±8.3       9.8 ± 6.5        0.18

  In-hospital death        8 (3.5)            34 (13.0)           \<0.01    7 (2.9)         14 (10.1)        \<0.01    16 (5.6)        25 (13.7)        \<0.01

  MACPE                    52 (22.5)          99 (37.5)           \<0.01    63 (26.1)       45 (32.4)        0.19      87 (30.4)       57 (31.3)        0.83
  ------------------------ ------------------ ------------------- --------- --------------- ---------------- --------- --------------- ---------------- ---------

LOS: length of stay, MACPE: major adverse cardiopulmonary events, SBP: Systolic blood pressure .

We also performed a survival analysis to compare the all-cause mortality in the follow-up period between patients with different levels of MPV ([Figure 3](#F3){ref-type="fig"}) and the Kaplan-Meier curve showed no difference between these two groups in terms of intermediate- to long-term mortality (log-rank test; *P* = 0.8).
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Discussion {#s4}
==========

In this study, we explored the prognostic value of platelet indices in predicting adverse outcomes in patients with acute PTE. Several key findings are noteworthy. MPV was higher in patients who had adverse events during their index hospital stay as compared to those who did not. All three indices had fair to good predictive performance in predicting in-hospital all-cause death. They performed poorer in predicting long-term mortality or in predicting a composite endpoint including death and other non-fatal adverse events. Despite having fair performance, established PTE risk scoring models such as PESI outperform these indices in predicting adverse outcomes.

Larger platelets have more glycoprotein Ib and glycoprotein IIb/IIIa receptors, and they release higher levels of thromboxane A2, platelet factor 4 and β-thromboglobulin,^[@R5],[@R7],[@R12]^ hence they are more metabolically and enzymatically reactive and have higher thrombotic potentials.^[@R12]^ Platelets are involved in the pathogenesis of various diseases and elevated MPV has been associated with higher risk of adverse events in several disease conditions, such as acute coronary syndrome, stroke.^[@R13],[@R14]^ Higher MPV is also reported in the venous thromboembolism setting.^[@R15],[@R16]^ It has been reported to be a risk indicator for predicting the possibility of PTE in patients with unprovoked DVT.^[@R16],[@R17]^

Considering the presence of hypercoagulable state in venous thromboembolism and acute PTE and purported pro-thrombotic properties of platelets with higher MPV, it is expected to see a correlation between high MPV and clinical outcomes in this specific disease. Several studies have explored and demonstrated its diagnostic value in diagnosing acute PTE among the suspected patients.^[@R18]^ Our findings were in line with the findings of Kostrubiec et al which reported MPV to be an independent predictor of mortality in patients with acute PTE.^[@R19]^ A study by Günay et al showed that MPV and PDW can be useful in determining the severity of pulmonary vascular bed obstruction in PTE (i.e. massive vs submassive).^[@R20]^ Several studies suggested its correlation with right ventricular (RV) dimensions and the severity of RV dysfunction.^[@R15],[@R21],[@R22]^ Nevertheless, these studies were not consistent so far and some studies failed to find a correlation between MPV and disease severity.^[@R21],[@R23]^

In this study, the simplified PESI outperformed the platelet indices in prognosticating patients with acute PTE. Akgülü et al in a study showed that the predictive performance of extensively-studied risk scores such as the simplified PESI can be improved by addition of factors such as MPV.^[@R24]^

Like several previous studies, MPV correlated inversely with the total platelet count. This can be attributed to the consumption of platelets for thrombus formation and a compensatory production of larger platelets from megakaryocytes in the bone marrow.^[@R22],[@R25]^

Previous studies have showed a relationship between PLR and a high risk of in-hospital mortality in patients with acute PTE and found it to be correlated with established risk scores (e.g. simplified PESI).^[@R23],[@R26]^ Similarly, in this study, PLR was correlated with the simplified PESI, whilst the other two indices lacked such correlation. However, the PLR levels were not different between patient with and without adverse events and it only had a fair predictive performance in predicting in-hospital mortality.

It is important to delineate the pathophysiologic mechanisms with which the activated platelet is linked to acute PTE itself and moreover to the adverse events in patients with acute PTE. A vicious cycle between the platelet activation and pulmonary vascular bed obstruction is the most legitimate explanation. The mechanisms that contribute include sympathetic activation resulted from hypoxemia^[@R15],[@R27]^ which in turn leads to platelet activation and the release of angiotensin II, pulmonary vasoconstriction due to the release of thromboxane A2 from platelets,^[@R6],[@R28],[@R29]^ hypercoagulability secondary to an increase in the plasma levels of platelet factor-4 and β-thromboglobulin^[@R29]^ and increase in platelet-fibrinogen binding resulted from the overexpression of adhesion molecules such as P-selectin, glycoprotein Ib and glycoprotein IIb/IIIa in platelets.^[@R5],[@R30]^

There are several potential limitations to this study. This study was a single-center observational study and it was subject to biases that are innate to observational studies. Our study included patients of a single center and one snap shot of blood samples has been utilized at the time of admission. Serial measurement and study of temporal changes were not possible in our study setting. There may be also racial and ethnical differences in normal ranges in a given population.

Conclusion {#s5}
==========

In conclusion, platelet indices had only fair-to-good predictive performance in predicting in-hospital all-cause death. Despite having fair prognostication, established PTE risk scoring models such as simplified PESI outperform these indices in predicting adverse outcomes.
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